The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring new frontiers ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

The semaglutide trial showed effect sizes "in the medium to large range," he said, although he urged caution about the results since the trial "was the first to look at this question in a ...

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.